In a new study entitled “T Cells Derived From Human Melanoma Draining Lymph Nodes Mediate Melanoma-specific Antitumor Responses In Vitro and In Vivo in Human Melanoma Xenograft Model” researcher’s at the UH Seidman Cancer Center established a protocol where they retrieved T cells from lymph nodes of melanoma patients and proceeded to their expansion and activation in vitro.
MRV Research
Caladrius Biosciences Doses First Patient in Phase III Cell Therapy Trial for Melanoma
New York-based Caladrius Biosciences, Inc., a company at the forefront of cell therapy, has recently announced the dosing of the first patient in its Intus Phase III clinical trial. This study intends to determine the effectiveness of Caladrius’ patient-specific targeted cancer immunotherapy candidate, CLBS20 (also known as NBS20), which will be tested on patients diagnosed with either stage III recurrent or stage IV metastatic melanoma. The news follows the award of a $17.7 million research grant from the California Institute for Regenerative Medicine.
T Cells From Melanoma Patients Show Immunotherapy Promise
T cells derived from patients with melanoma can provoke a protective immune response against the disease, according to the results of a new study.
Partner-assisted skin-exam training improves skin exam practices in patients with melanoma
Patients with melanoma who participated in a skin self-exam intervention with their partners continued to practice skin self-exams up to 12 months after their training, according to recent research.